Revive Therapeutics Ltd. announced that Tessio Rebello, Ph.D., will join the Company as a clinical advisor for the Company. Dr. Rebello previously held the position of Vice President of Clinical Development at VIRxSYS Corporation where he led the successful launch of anti-sense, gene therapy (VRX496), Phase 2 clinical trial for the treatment of HIV-infected patients who fail to respond to conventional drug therapies and two other Phase 2 clinical trials involving the same drug.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.02 CAD | -20.00% | 0.00% | -33.33% |
1st Jan change | Capi. | |
---|---|---|
-33.33% | 6.09M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- RVV Stock
- News Revive Therapeutics Ltd.
- Revive Therapeutics Appoints Tessio Rebello as Clinical Advisor